Skip to content
MedsAcross

Molecule

Paromomycin

Also known as paromomycin sulfate
Available on requestGastroenterology
Presentations
1
Brands
1
Manufacturers
1
Available from stock
0

Paromomycin is an antiprotozoal indicated for intestinal amebiasis–acute and chronic (NOTE-It is not effective in extraintestinal amebiasis), management of hepatic coma–as adjunctive therapy. It is available as capsules for oral use. MedsAcross supplies Paromomycin for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.

Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review

Key facts

Pharmacological class
Antiprotozoal
ATC classification
A07AA06 Paromomycin · Diarrhoea treatments and intestinal anti-inflammatories, subgroup A07A, subgroup A07AA
US FDA first approval
Approved
EU status
Not recorded
Orphan designation
Not recorded
WHO essential medicine
Not recorded
India (CDSCO)
Not yet confirmed against CDSCO approval lists
Routes
Oral
Dosage forms
Capsule
Identifiers
UNII 61JJC8N5ZKRxCUI 7934CAS 7542-37-2DrugBank DB01421Q415625

Clinical information

From the regulator-approved product information. Each section names its source.

Uses

Paromomycin sulfate is indicated for intestinal amebiasis–acute and chronic (NOTE-It is not effective in extraintestinal amebiasis), management of hepatic coma–as adjunctive therapy. To reduce the development of drug-resistant bacteria and maintain the effectiveness of HUMATIN™ Capsules and other antibacterial drugs, HUMATIN™ Capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

Source: US FDA prescribing information

Dosing overview

Intestinal amebiasis: Adults and Pediatric Patients: Usual dose—25 to 35 mg/kg body weight daily, administered in three doses with meals, for five to ten days. Management of hepatic coma: Adults: Usual dose—4 g daily in divided doses, given at regular intervals for five to six days.

Source: US FDA prescribing information

Contraindications

Paromomycin sulfate is contraindicated in individuals with a history of previous hypersensitivity reactions to it. It is also contraindicated in intestinal obstruction.

Source: US FDA prescribing information

Warnings and precautions

Prescribing HUMATIN™ Capsules in the absence of a proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria. The use of this antibiotic, as with other antibiotics, may result in an overgrowth of nonsusceptible organisms, including fungi. Constant observation of the patient is essential. If new infections caused by nonsusceptible organisms appear during therapy, appropriate measures should be taken. The drug should be used with caution in individuals with ulcerative lesions of the bowel to avoid renal toxicity through inadvertent absorption. Information for Patients Patients should be counseled that antibacterial drugs including HUMATIN™ Capsules should only be used to treat bacterial infections. They do not treat viral infections (e.g., the common cold).

Source: US FDA prescribing information

For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.

All presentations

1 presentations of Paromomycin, sorted by availability.

MedicineManufacturerRegisterAvailability
Humatin 250 mg capsuleOralWaylis TherapeuticsUS FDAAvailable on request

Brands by market

1 brand names across 1 markets.

Brand names by country

United States

Manufacturers

Regulatory status

Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.

RegisterStatusSource
US FDAApprovedDrugs@FDA
EU (EMA)Not recorded—
India (CDSCO)Not yet confirmed against CDSCO approval lists—
United StatesRegisteredUS FDA (NDC directory, openFDA)Checked 12 November 2026

Conditions

Conditions linked to Paromomycin in public data. This is not a list of approved uses, see the clinical information.

Questions and answers

Is Paromomycin available for export from India?

Yes, on request. MedsAcross lists 1 presentations of Paromomycin and sources them for licensed hospitals, importers and physicians against valid import documents.

What brand names does Paromomycin have?

The catalogue lists 1 brand names for Paromomycin, including Humatin.

Does Paromomycin need cold chain shipping?

No listed presentation of Paromomycin is recorded as needing a cold chain. Storage conditions are shown on each presentation page.

Which ATC class is Paromomycin in?

Paromomycin is classified under ATC code A07AA06 (Paromomycin).

References

  1. Humatin prescribing information (Waylis Therapeutics). U.S. National Library of Medicine, DailyMed. Retrieved 13 November 2025

Request Paromomycin for export supply

Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.